SenesTech: Glenbrook reports 40.51% ownership stake

Glenbrook reported paying approximately $4.43 million for shares during its reporting-obligation period, excluding brokerage commissions.

Rhea-AI Filing Summary

SenesTech, Inc. (SNES) is the issuer in Glenbrook Capital Management’s Schedule 13D amendment, which reports Glenbrook beneficially owned 2,196,973 shares, or 40.51% of the common stock. Glenbrook reported shared voting and dispositive power over those shares and no sole voting or dispositive power. The ownership percentage is based on 5,423,542 shares outstanding as of August 4, 2026.

Glenbrook said it paid approximately $4.43 million, excluding brokerage commissions, to acquire shares during the period it was subject to reporting obligations; that amount excludes the price of shares acquired or sold before the period. It stated that all transactions since Amendment No. 2 were in the open market. Glenbrook also disclosed that it commissioned a rodent-control market study from Sandstrom Partners in April 2026, at its expense, and that the results were presented to SenesTech’s Board. On October 28, 2026, SenesTech announced Sandstrom’s engagement as a strategic advisor on marketing and branding; Glenbrook disclosed a minority ownership interest in Sandstrom.

Key Figures

Beneficially owned shares: 2,196,973 shares Ownership percentage: 40.51% Shares outstanding: 5,423,542 shares +1 more

4 metrics

Beneficially owned shares 2,196,973 shares SenesTech common stock

Ownership percentage 40.51% Based on shares outstanding as of August 4, 2026

Shares outstanding 5,423,542 shares As of August 4, 2026

Share acquisition amount Approximately $4.43 million Paid during the period Glenbrook was subject to reporting obligations; excludes brokerage commissions

Key Terms

beneficially owned, shared voting power, shared dispositive power, Section 13(d)

4 terms

beneficially owned regulatory

"aggregate amount beneficially owned by each reporting person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power regulatory

"Shared Voting Power 2,196,973.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power regulatory

"Shared Dispositive Power 2,196,973.00"

Section 13(d) regulatory

"reporting obligations under Section 13(d) or 13(g)"

A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SNES shares does Glenbrook Capital Management beneficially own?

Glenbrook Capital Management reported beneficial ownership of 2,196,973 SenesTech common shares, or 40.51%. The percentage is based on 5,423,542 shares outstanding as of August 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 09:07 PM EDT Accepted by SEC EDGAR 10/30/2026 - 09:06 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

SenesTech, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

81720R604

(CUSIP Number)

Glenbrook Capital Management
2207, Suite B, Bellanca St.
Minden, NV, 89423
650-441-9525

Ele Klein & Danny Goldstein
McDermott Will & Schulte LLP, 919 Third Avenue
New York, NY, 10022
212-756-2446

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/28/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 81720R604

1

Name of reporting person

GLENBROOK CAPITAL MANAGEMENT

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,196,973.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,196,973.00

11

Aggregate amount beneficially owned by each reporting person

2,196,973.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

40.51 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Based on 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: SenesTech, Inc.
(c)	Address of Issuer's Principal Executive Offices: 13430 NORTH DYSART ROAD, SUITE 105, SURPRISE, ARIZONA , 85379.
Item 1 Comment: This Amendment No. 3 ("Amendment No. 3") amends the statement on Schedule 13D filed with the SEC on July 23, 2026, as amended by Amendment No. 1 filed with the SEC on October 19, 2026 and Amendment No. 2 filed with the SEC on October 22, 2026 (as amended, the "Schedule 13D") with respect to the Common Stock of the Issuer. This Amendment No. 3 amends Item 3, Item 4, and 5(a)-(c), as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 is hereby amended and restated as follows: Funds for the purchase of the securities reported herein were derived from the general working capital of the Glenbrook Funds and Accounts. A total of approximately $4.43 million (excluding brokerage commissions) was paid to acquire shares of Common Stock during the period in which the Reporting Person has been subject to reporting obligations under Section 13(d) or 13(g) of the Act with respect to the Common Stock. Such amount does not include the price of shares of Common Stock acquired and/or sold by the Reporting Person prior to such period.
Item 4.	Purpose of Transaction
	Item 4 is hereby amended and supplemented by adding the following: In April 2026, the Reporting Person commissioned, at its expense, a strategic study of the rodent control market by Sandstrom Partners, Inc. ("Sandstrom"), the results of which were presented to the Board. On October 28, 2026, the Issuer announced that it had engaged Sandstrom as a strategic advisor on marketing and branding. The Reporting Person holds a minority ownership interest in Sandstrom.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated as follows: See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of shares of Common Stock beneficially owned by the Reporting Person. The aggregate percentage of shares of Common Stock reported to be beneficially owned by the Reporting Person is based upon 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026.
(b)	Item 5(b) is hereby amended and restated as follows: See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	Item 5(c) is hereby amended and restated as follows: All transactions in the shares of Common Stock effected by the Reporting Person since the filing of Amendment No. 2, which were all in the open market, are set forth in Schedule A hereto, and are incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	EX 99.1 TRANSACTIONS IN SECURITIES OF THE ISSUER

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GLENBROOK CAPITAL MANAGEMENT

Signature:	/s/ Robert W. Lishman
Name/Title:	Robert W. Lishman, Director
Date:	10/30/2026